NCT05118724 analyzes the efficacy of atezolizumab versus atezolizumab combined with IMM-101 (a suspension of heat-killed Mycobacterium obuense, which induces CD8+ T cell responses) in dMMR/MSI-H stage III CRC patients who do not qualify for or refuse oxaliplatin-based adjuvant chemotherapy, with plans to enroll 120 patients, with DFS as the primary endpoint and OS as the secondary endpoint. Here, CD8A is linked to colorectal carcinoma.